TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01088841

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactisole
Description: lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactisole
Description: lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactisole
Description: lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Study: NCT03000257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab Tesirine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous infusion
Study: NCT04068506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg Tab
Description: Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 600 mg Tab
Description: Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
Study: NCT03899155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT06549712

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identify genetic determinants of the predisposition to develop respiratory failure
Description: To identify the main common genetic determinants of severe COVID-19 by conducting a GWAS: in first phase we will compare SARS-CoV-2 positive patients with severe lung affection to healthy controls from the same geographic area, in order to provide initial data informing the research in the field in a timely fashion. This will be conducted in close collaboration with the University of Kiel COVID-19 genomic initiative. Later on, we will proceed to assess objectives 1 and 2 in the full cohort, including also infected controls who did not developed clinically significant symptoms

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identify genetic determinants of the predisposition to develop respiratory failure
Description: To provide extensive genetic characterization of all patients managed at the Fondazione in order to facilitate other groups working on specific projects (e.g. on candidate genes such as SERPINA1 and ACE2 by the Intensive Care and Cardiology Units and other that may emerge from upcoming projects), in a large population and in a very timely fashion, and without incurring in any additional expenses for the Fondazione research network, and coordinate research efforts.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identify genetic determinants of the predisposition to develop respiratory failure
Description: To provide a coordination to manage the collaboration with other research consortia in the field, e.g. the An anonymized GWAS to urgently query host genetic predisposition to severe COVID-19 (SARS-CoV-2 infection) lung disease, and the COVID-19 Host Genetic Initiative (https://www.covid19hg.org). Indeed, collaboration among large networks analyzing several thousand cases will be ultimately necessary to clarify the genetic basis of COVID-19 susceptibility, and large collaborative networks are essential instruments for conducting human genetic research.
Study: NCT01867983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight gain prevention and smoking cessation
Description: The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight gain prevention and smoking cessation
Description: The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls.
Study: NCT04294615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT through a naso-jejunal tube
Description: Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FMT through TET
Description: Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
Study: NCT02777606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Si-Ni-Tang
Description: Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
Study: NCT02030197

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRISP Program
Description: Educational program to improve self-efficacy, loneliness and depression

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: no treatment
Study: NCT01335724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac diethylamine 1.16% gel
Description: Diclofenac diethylamine 1.16% gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel
Study: NCT03899155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT02793817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 1% Ophthalmic Suspension dosed BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Study: NCT02499900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone®
Description: Subcutaneous Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copaxone®
Description: Subcutaneous Injections
Study: NCT04135560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 and Vehicle
Description: PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
Study: NCT03899155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study: NCT04135560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
Study: NCT03899155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days
Study: NCT01867983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation
Description: The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
Study: NCT03899155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Specified dose on specified days
Study: NCT03762915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline HCl microspheres
Description: Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
Study: NCT04063215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences autologous adipose-derived mesenchymal stem cells
Study: NCT04627064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6482
Description: Tablet taken orally
Study: NCT03460080

Intervention type: DIAGNOSTIC_TEST
Intervention: AFP-L3 and PIVKA-II in HCC
Description: Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: AFP-L3 and PIVKA-II in HCC
Description: Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI
Study: NCT04135560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 safe concentration or vehicle BID applied to 10% BSA
Study: NCT04953819

Intervention type: OTHER
Intervention: Revascularization
Description: Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease

Intervention type: OTHER
Intervention: Medical therapy
Description: Optimal medical therapy for coronary artery disease
Study: NCT03762889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyeprotx™ General Anesthesia Protective Goggles
Description: Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid Tape
Description: Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Ointment
Description: Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
Study: NCT03983265

Intervention type: OTHER
Group type: OTHER
Intervention: Bilateral Sagittal Split Osteotomy
Description: after BSSO condyle will be re positioned by using computer guided device
Study: NCT02374814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: Compare dose schedule and route of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: Compare dose schedule and route of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: Compare dose schedule and route of administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: Compare dose schedule and route of administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02052726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine with adjuvant
Description: C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered at Month 0, 1, and 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine with adjuvant
Description: C. difficile vaccine with adjuvant administered at day 1, 8, 30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered at Day 1, 8, and 30.
Study: NCT03074292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
Study: NCT04627675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORVax
Description: DNA-encodable coronaviral vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORVax
Description: DNA-encodable coronaviral vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORVax
Description: DNA-encodable coronaviral vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORVax
Description: DNA-encodable coronaviral vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-12 plasmid
Description: cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-12 plasmid
Description: cytokine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator
Description: electroporation system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator
Description: electroporation system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator
Description: electroporation system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator
Description: electroporation system
Study: NCT04559022

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fat Grafting
Description: This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
Study: NCT03430843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 125 mg/m\^2 administered IV
Study: NCT03988985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GP-targeted feedback
Description: The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GP-targeted feedback
Description: The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
Study: NCT02321644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 Active-ingredient-in-capsule and formulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 Active-ingredient-in-capsule and formulated tablet
Study: NCT05862454

Intervention type: DRUG
Intervention: Magnesium
Description: Magnesium injection therapy